<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568802</url>
  </required_header>
  <id_info>
    <org_study_id>SU-11012007-781</org_study_id>
    <secondary_id>79233</secondary_id>
    <nct_id>NCT00568802</nct_id>
    <nct_alias>NCT00084006</nct_alias>
  </id_info>
  <brief_title>A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients</brief_title>
  <official_title>A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The objectives of this trial are: to establish a safety profile for use of Hydroxyurea in
      children with Types II and III Spinal Muscular Atrophy; to identify reliable outcome measures
      for HU treatment in Types II and III SMA; and to detect the clinical efficacy of HU treatment
      in children with Types II and III SMA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SMA is a neuromuscular disorder characterized by degeneration of spinal cord motor neurons
      and muscular atrophy. SMA is classified into three clinical subtypes according to the
      severity and age of onset (Types I, II and III). Type II (intermediate) SMA has its onset in
      early childhood (prior to 18 months) and is characterized by the failure to stand or walk
      unassisted. Individuals with Type III SMA (mild SMA or Kugelberg-Welander disease) typically
      develop symptoms after 18 months of age and display a wide range of clinical heterogeneity.
      The clinical spectrum ranges from rapid progressive weakness resulting in wheelchair
      dependence in late childhood to patients being able to walk in adult years and living
      productive and independent lifestyles for the majority of their lives.

      In our laboratory, our preliminary results indicate that HU treatment significantly increases
      both SMN mRNA expression and intact SMN protein levels in vitro. These data confirm previous
      observations that in vitro treatments of SMA lymphocytes with hydroxyurea resulted in
      augmentation of the SMN2 gene expression in a dose and time related manner. Based on these
      exciting pre-clinical data, coupled with the well-documented side-effect profile of HU in
      children, we are conducting a pilot clinical trial using HU in children with Types II and III
      SMA. This clinical trial study is intended to establish the safety profile in children with
      Types II and III SMA; to identify reliable outcome measures; and to detect the possible
      clinical efficacy of HU treatment in children with Types II and III SMA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2004</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Functional Motor Testing, Including Gross Motor Function Measure (GMFM) and Timed Motor Tests</measure>
    <time_frame>Up to 6 years, 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Frequency of Adverse Events/Lab Abnormalities</measure>
    <time_frame>Up to 6 years, 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Testing</measure>
    <time_frame>Up to 6 years, 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Unit Number Estimation (MUNE)</measure>
    <time_frame>Up to 6 years, 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Assays: SMN Protein and SMN mRNA</measure>
    <time_frame>Up to 6 years, 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Muscular Atrophy, Spinal</condition>
  <arm_group>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <arm_group_label>Hydroxyurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match hydroxyurea</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1. Laboratory confirmation of a homozygous deletion or mutation of the
        SMN1 gene 2. (Type II) Can sit independently but cannot walk without support by the age of
        16 months and never achieve independent walking thereafter; OR (Type III) Can walk
        independently within the first 2 years of life, but showing rapid progression of weakness
        resulting in the loss of independent ambulation by 6 years of age 3. Patient is older than
        16 months and younger than 8 years old at the time of enrollment

        Exclusion Criteria:1. Known hematological disorders, other systemic disorders, or severe
        birth asphyxia 2. Participation in SMA clinical trials for other experimental drugs 3.
        Requiring continuous respiratory support before the initiation of HU treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Ching H. Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <results_first_submitted>September 6, 2019</results_first_submitted>
  <results_first_submitted_qc>September 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2019</results_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Spinal Muscular Atrophies of Childhood</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Data are presented for all participants because data relating to arm assignment are no longer accessible; the Principal Investigator (PI) has left institution and all efforts to locate the data have been exhausted.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Participants received hydroxyurea, or placebo to match hydroxyurea.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data are presented for all participants because data relating to arm assignment are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants received hydroxyurea, or placebo to match hydroxyurea.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Functional Motor Testing, Including Gross Motor Function Measure (GMFM) and Timed Motor Tests</title>
        <time_frame>Up to 6 years, 2 months</time_frame>
        <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Hydroxyurea</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match hydroxyurea</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Functional Motor Testing, Including Gross Motor Function Measure (GMFM) and Timed Motor Tests</title>
          <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Frequency of Adverse Events/Lab Abnormalities</title>
        <time_frame>Up to 6 years, 2 months</time_frame>
        <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Hydroxyurea</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match hydroxyurea</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Frequency of Adverse Events/Lab Abnormalities</title>
          <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function Testing</title>
        <time_frame>Up to 6 years, 2 months</time_frame>
        <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Hydroxyurea</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match hydroxyurea</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Testing</title>
          <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Motor Unit Number Estimation (MUNE)</title>
        <time_frame>Up to 6 years, 2 months</time_frame>
        <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Hydroxyurea</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match hydroxyurea</description>
          </group>
        </group_list>
        <measure>
          <title>Motor Unit Number Estimation (MUNE)</title>
          <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Assays: SMN Protein and SMN mRNA</title>
        <time_frame>Up to 6 years, 2 months</time_frame>
        <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Hydroxyurea</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match hydroxyurea</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker Assays: SMN Protein and SMN mRNA</title>
          <population>Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 years, 2 months</time_frame>
      <desc>Adverse events data are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hydroxyurea</title>
          <description>Hydroxyurea</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to match hydroxyurea</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Stanford University</organization>
      <email>clinicaltrials-gov@lists.stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

